Mednax, Inc. (MD): Price and Financial Metrics

Mednax, Inc. (MD)

Today's Latest Price: $19.99 USD

0.97 (-4.63%)

Updated Feb 21 12:00am

Add MD to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 66 in Medical - Services

See all "A" rated Strong Buy stocks

MD Stock Summary

  • MD's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.4 -- higher than merely 3.8% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of Mednax Inc's sales and general administrative expense to its total operating expenses; just 10.24% of US stocks have a lower such ratio.
  • Over the past twelve months, MD has reported earnings growth of -394.01%, putting it ahead of only 3.8% of US stocks in our set.
  • Stocks that are quantitatively similar to MD, based on their financial statements, market capitalization, and price volatility, are TPRE, SXC, CPG, ETM, and NM.
  • Visit MD's SEC page to see the company's official filings. To visit the company's web site, go to
MD Daily Price Range
MD 52-Week Price Range

MD Stock Price Chart More Charts

MD Price/Volume Stats

Current price $19.99 52-week high $36.35
Prev. close $20.96 52-week low $19.45
Day low $19.45 Volume 3,222,900
Day high $21.01 Avg. volume 1,096,680
50-day MA $26.45 Dividend yield N/A
200-day MA $24.74 Market Cap 1.69B

Mednax, Inc. (MD) Company Bio

MEDNAX Inc. provides neonatal, anesthesia, maternal-fetal, and other pediatric subspecialties physician services in the United States and Puerto Rico. The company was founded in 1979 and is based in Sunrise, Florida.

MD Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$19.99$11.9 -55%

We started the process of determining a valid price forecast for Mednax Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Mednax Inc ranked in the 35st percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Mednax Inc, consider:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 52. Notably, its equity weight is greater than just 13.17% of US equities in the Healthcare sector yielding a positive free cash flow.
  • Its compound free cash flow growth rate, as measured over the past 5.51 years, is -0.03% -- higher than merely 24.99% of stocks in our DCF forecasting set.
  • Mednax Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -12.02. This coverage rate is greater than that of merely 5.43% of stocks we're observing for the purpose of forecasting via discounted cash flows.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as MD, try IQV, CHE, LHCG, MDT, and NUVA.

MD Latest News Stream

Event/Time News Detail
Loading, please wait...

MD Latest Social Stream

Loading social stream, please wait...

View Full MD Social Stream

MD Price Returns

1-mo -25.33%
3-mo -26.37%
6-mo -3.01%
1-year -44.44%
3-year -71.28%
5-year -72.00%
YTD -28.07%
2019 -15.79%
2018 -38.25%
2017 -19.83%
2016 -6.98%
2015 8.40%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6684 seconds.